Stereotaxis Inc (STXS)

$2.5

+0.01

(+0.4%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Stereotaxis Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 7.85M → 4.56M (in $), with an average decrease of 21.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -5.70M → -5.04M (in $), with an average increase of 13.2% per quarter

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 25.5% return, outperforming this stock by 93.3%

Performance

  • $2.43
    $2.55
    $2.50
    downward going graph

    2.8%

    Downside

    Day's Volatility :4.7%

    Upside

    1.96%

    downward going graph
  • $1.33
    $3.29
    $2.50
    downward going graph

    46.8%

    Downside

    52 Weeks Volatility :59.57%

    Upside

    24.01%

    downward going graph

Returns

PeriodStereotaxis IncSector (Health Care)Index (Russel 2000)
3 Months
25.76%
-0.7%
0.0%
6 Months
66.0%
9.2%
0.0%
1 Year
41.48%
3.5%
-1.3%
3 Years
-67.66%
12.3%
-22.1%

Highlights

Market Capitalization
204.5M
Book Value
$0.2
Earnings Per Share (EPS)
-0.27
PEG Ratio
0.0
Wall Street Target Price
4.6
Profit Margin
-77.37%
Operating Margin TTM
-116.19%
Return On Assets TTM
-28.64%
Return On Equity TTM
-76.93%
Revenue TTM
26.8M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
-37.5%
Gross Profit TTM
18.5M
EBITDA
-21.2M
Diluted Eps TTM
-0.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.23
EPS Estimate Next Year
-0.17
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.07

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Stereotaxis Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 84.0%

Current $2.50
Target $4.60

Company Financials

FY18Y/Y Change
Revenue
29.3M
↓ 5.77%
Net Income
116.8K
↓ 101.98%
Net Profit Margin
0.4%
↑ 19.3%
FY19Y/Y Change
Revenue
28.9M
↓ 1.51%
Net Income
-4.2M
↓ 3725.49%
Net Profit Margin
-14.65%
↓ 15.05%
FY20Y/Y Change
Revenue
26.6M
↓ 7.86%
Net Income
-6.5M
↑ 52.44%
Net Profit Margin
-24.23%
↓ 9.58%
FY21Y/Y Change
Revenue
35.0M
↑ 31.51%
Net Income
-8.4M
↑ 30.75%
Net Profit Margin
-24.09%
↑ 0.14%
FY22Y/Y Change
Revenue
28.1M
↓ 19.63%
Net Income
-19.2M
↑ 126.98%
Net Profit Margin
-68.04%
↓ 43.95%
FY23Y/Y Change
Revenue
26.8M
↓ 4.89%
Net Income
-20.7M
↑ 8.16%
Net Profit Margin
-77.37%
↓ 9.33%
Q3 FY22Q/Q Change
Revenue
7.7M
↑ 24.46%
Net Income
-4.8M
↓ 6.03%
Net Profit Margin
-62.45%
↑ 20.27%
Q4 FY22Q/Q Change
Revenue
7.3M
↓ 4.65%
Net Income
-3.9M
↓ 19.45%
Net Profit Margin
-52.76%
↑ 9.69%
Q1 FY23Q/Q Change
Revenue
6.5M
↓ 10.31%
Net Income
-4.9M
↑ 27.6%
Net Profit Margin
-75.06%
↓ 22.3%
Q2 FY23Q/Q Change
Revenue
7.9M
↑ 20.02%
Net Income
-5.0M
↑ 0.85%
Net Profit Margin
-63.07%
↑ 11.99%
Q3 FY23Q/Q Change
Revenue
7.8M
↓ 0.76%
Net Income
-5.7M
↑ 15.13%
Net Profit Margin
-73.18%
↓ 10.11%
Q4 FY23Q/Q Change
Revenue
4.6M
↓ 41.47%
Net Income
-5.0M
↓ 11.69%
Net Profit Margin
-110.41%
↓ 37.23%
FY18Y/Y Change
Total Assets
18.5M
↑ 73.57%
Total Liabilities
11.2M
↓ 64.05%
FY19Y/Y Change
Total Assets
43.6M
↑ 135.41%
Total Liabilities
15.1M
↑ 33.95%
FY20Y/Y Change
Total Assets
55.5M
↑ 27.24%
Total Liabilities
15.2M
↑ 1.11%
FY21Y/Y Change
Total Assets
61.0M
↑ 9.97%
Total Liabilities
21.6M
↑ 41.6%
FY22Y/Y Change
Total Assets
53.4M
↓ 12.42%
Total Liabilities
21.5M
↓ 0.36%
FY23Y/Y Change
Total Assets
41.9M
↓ 21.54%
Total Liabilities
20.0M
↓ 6.96%
Q3 FY22Q/Q Change
Total Assets
56.1M
↓ 1.06%
Total Liabilities
22.7M
↑ 7.43%
Q4 FY22Q/Q Change
Total Assets
53.4M
↓ 4.75%
Total Liabilities
21.5M
↓ 5.46%
Q1 FY23Q/Q Change
Total Assets
50.7M
↓ 5.06%
Total Liabilities
21.4M
↓ 0.31%
Q2 FY23Q/Q Change
Total Assets
48.3M
↓ 4.72%
Total Liabilities
21.3M
↓ 0.34%
Q3 FY23Q/Q Change
Total Assets
44.5M
↓ 7.84%
Total Liabilities
20.2M
↓ 5.23%
Q4 FY23Q/Q Change
Total Assets
41.9M
↓ 5.88%
Total Liabilities
20.0M
↓ 1.19%
FY18Y/Y Change
Operating Cash Flow
-2.5M
↓ 45.52%
Investing Cash Flow
-265.5K
↑ 225.44%
Financing Cash Flow
9.9M
↓ 16932.07%
FY19Y/Y Change
Operating Cash Flow
-4.6M
↑ 81.29%
Investing Cash Flow
-29.5K
↓ 88.89%
Financing Cash Flow
24.0M
↑ 142.22%
FY20Y/Y Change
Operating Cash Flow
-3.5M
↓ 23.93%
Investing Cash Flow
-70.9K
↑ 140.44%
Financing Cash Flow
17.3M
↓ 27.85%
FY21Y/Y Change
Operating Cash Flow
-2.9M
↓ 16.11%
Investing Cash Flow
-1.4M
↑ 1869.91%
Financing Cash Flow
547.4K
↓ 96.84%
FY22Y/Y Change
Operating Cash Flow
-8.4M
↑ 185.65%
Investing Cash Flow
-22.1M
↑ 1482.0%
Financing Cash Flow
220.0K
↓ 59.81%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.5M
↑ 122.78%
Investing Cash Flow
-205.0K
↓ 68.46%
Financing Cash Flow
48.0K
↓ 15.79%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.6M
↑ 0.75%
Investing Cash Flow
-20.1M
↑ 9697.56%
Financing Cash Flow
61.0K
↑ 27.08%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.8M
↑ 9.8%
Investing Cash Flow
-349.0K
↓ 98.26%
Financing Cash Flow
56.0K
↓ 8.2%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.9M
↑ 4.6%
Investing Cash Flow
20.1M
↓ 5866.19%
Financing Cash Flow
-26.0K
↓ 146.43%

Technicals Summary

Sell

Neutral

Buy

Stereotaxis Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Stereotaxis Inc
Stereotaxis Inc
-0.8%
66.0%
41.48%
-67.66%
-25.45%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-5.82%
34.39%
22.79%
25.53%
121.17%
Resmed Inc.
Resmed Inc.
-7.48%
21.97%
-22.07%
-14.55%
76.22%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.22%
-8.52%
-10.74%
-8.49%
2.56%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-5.55%
0.4%
0.02%
15.6%
231.7%
Alcon Ag
Alcon Ag
-2.84%
9.33%
9.99%
5.59%
44.33%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Stereotaxis Inc
Stereotaxis Inc
NA
NA
0.0
-0.23
-0.77
-0.29
NA
0.2
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
74.08
74.08
7.13
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
29.41
29.41
1.75
7.41
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
53.47
53.47
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
47.82
47.82
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
40.04
40.04
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Stereotaxis Inc
Stereotaxis Inc
Buy
$201.2M
-25.45%
NA
-77.37%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$132.1B
121.17%
74.08
25.24%
Resmed Inc.
Resmed Inc.
Buy
$26.1B
76.22%
29.41
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.4B
2.56%
53.47
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.6B
231.7%
47.82
20.12%
Alcon Ag
Alcon Ag
Buy
$39.1B
44.33%
40.04
10.3%

Corporate Announcements

  • Stereotaxis Inc Earnings

    Stereotaxis Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.

Organization
Stereotaxis Inc
Employees
122
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Industry
Medical Specialties

Discover More

FAQs